Oral Amiodarone Dosing Regimen
For ventricular arrhythmias, load with 800-1,600 mg per day in divided doses until a cumulative total of 10 grams is achieved, then maintain on 200-400 mg daily; for atrial fibrillation, load with 600-800 mg per day in divided doses until 10 grams total is reached, then maintain on 200 mg daily. 1
Loading Phase Strategy
The loading approach differs based on arrhythmia type and clinical urgency:
Ventricular Arrhythmias (Inpatient)
- Loading dose: 800-1,600 mg/day in divided doses
- Duration: Continue until cumulative 10 grams administered
- Maintenance: 200-400 mg/day 1
At typical loading doses of 1,200-1,600 mg/day, this 10-gram target is reached in approximately 6-8 days. The higher end of the loading range (1,600 mg/day) achieves therapeutic effect faster but requires closer monitoring for bradycardia and QT prolongation.
Atrial Fibrillation (Inpatient or Outpatient)
- Loading dose: 600-800 mg/day in divided doses
- Duration: Until cumulative 10 grams achieved
- Maintenance: 200 mg/day 1
This lower loading dose reflects the generally less urgent nature of atrial fibrillation management compared to life-threatening ventricular arrhythmias. At 600-800 mg/day, reaching 10 grams takes approximately 12-17 days.
Practical Loading Regimen
A more structured approach based on pharmacokinetic modeling suggests: 1,600 mg/day for 2 days, 1,200 mg/day for 5 days, 1,000 mg/day for 7 days, 800 mg/day for 7 days, 600 mg/day for 7 days, then 400 mg/day for 62 days before transitioning to maintenance dosing 2. This regimen accounts for amiodarone's extraordinarily long terminal half-life of 55 days and achieves therapeutic concentrations more predictably.
Maintenance Dosing
The lowest effective maintenance dose should always be used to minimize the dose-dependent toxicity profile. While guidelines suggest 200-400 mg/day for ventricular arrhythmias and 200 mg/day for atrial fibrillation 1, clinical experience demonstrates that many patients can be maintained on even lower doses (194-206 mg/day average) with acceptable arrhythmia control and significantly reduced adverse effects 3.
Key Maintenance Principles:
- Start at the guideline-recommended dose (200-400 mg/day)
- Titrate downward based on clinical response and side effect profile
- Consider 343 mg/day (400 mg for 6 of 7 days per week) as a practical maintenance target 2
- Monitor closely, as doses above 300 mg/day are associated with higher toxicity rates 1
Transition from IV to Oral
When converting from intravenous to oral amiodarone, the duration of IV therapy determines the initial oral dose 1:
- IV < 1 week: Start 800-1,600 mg/day oral
- IV 1-3 weeks: Start 600-800 mg/day oral
- IV > 3 weeks: Start 400 mg/day oral
This accounts for the extensive tissue distribution and loading that has already occurred with IV administration.
Critical Monitoring Points
Adverse Effects to Monitor:
- Pulmonary toxicity (most serious): Subacute cough, dyspnea, interstitial infiltrates; occurs in 1% annually at doses ≤300 mg/day 1
- Bradycardia and QT prolongation: Dose-related, monitor ECG regularly
- GI effects: Constipation is extremely common (seen in majority of patients)
- Thyroid dysfunction: Occurs in 15-20% of patients; requires baseline and periodic TSH monitoring 4
- Hepatotoxicity: Monitor liver enzymes at baseline and periodically
- Corneal microdeposits: Nearly universal but rarely symptomatic 5
Common Pitfall:
The most dangerous aspect of amiodarone is its narrow toxic-therapeutic range combined with its prolonged loading phase. The first sign of antiarrhythmic failure may be sudden cardiac death 5. This underscores the importance of using the lowest effective dose and maintaining close follow-up, particularly during the first 6 months of therapy.
Dosing Adjustments
Because of amiodarone's 55-day terminal half-life 2, dose adjustments take weeks to reach steady state. After stopping amiodarone:
- 25% concentration decrease occurs in 3 days
- 50% decrease takes 36 days 2
This extraordinarily slow elimination makes anticipating the timing of dose adjustments particularly challenging and requires patience in clinical management.
Special Considerations
Avoid grapefruit juice during oral amiodarone therapy, as it inhibits CYP3A4-mediated metabolism and increases plasma levels 6. The frequency of adverse effects is directly related to total amiodarone exposure (dose × duration), making the use of the lowest effective dose paramount 1.